Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2019 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results

Type A meeting with U.S. FDA expected by early June to discuss FINTEPLA® Dravet syndrome NDA expected by early JuneFINTEPLA Dravet syndrome MAA accepted for review by EMAExclusive distribution...
May 07, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference

EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D.,...
May 01, 2019 16:47 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement...
May 01, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8

EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
April 08, 2019 16:01 ET | Source: Zogenix, Inc.

Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application

EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to...
April 01, 2019 17:17 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement...
March 25, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix to Present at Two Investor Conferences in April

EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management...
March 19, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan

EMERYVILLE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an...
March 01, 2019 16:51 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement...
February 28, 2019 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

Completed rolling submission of an NDA to the U.S. FDA and an MAA to the EMA for FINTEPLA® for the treatment of seizures associated with Dravet syndrome in February 2019-- EMA has accepted MAA for...